Revotar Biopharmaceuticals AG Starts Phase II Clinical Trial in COPD Patients with inhaled Bimosiamose
The trial is designed as a double-blind, placebo controlled, randomized, cross-over study comprising up to 60 non-smoking patients with moderate to severe COPD (GOLD II-III). Each subject will receive nebulized Bimosiamose solution or vehicle for 28 consecutive days twice daily in two subsequent periods according to a randomization plan and separated by a wash-out phase (cross-over). Co-alternative primary endpoints will be the difference of neutrophils counts and interleukin-8 levels in induced sputum following Bimosiamose and Placebo; secondary variables cover lung function parameters as well as cellular and non-cellular biomarkers. The study is conducted at 10 centers in Germany.
"There is a huge market need for efficacious and safe anti-inflammatory drugs in COPD considering the reported limited efficacy of inhaled corticosteroids (ICS) or even documented ICS resistance in COPD", added Dr Martin Pöhlchen, CEO of Revotar.
In contrast to oral PDE4 inhibitors, Bimosiamose is given locally by inhalation, directly targeting the inflammation in the lung. In recent assessments from regulatory authorities (e.g. IQWiG) inhalative treatment is preferred towards oral treatment in COPD, since better efficacy and faster onset may be achieved with less systemic side effects. Results are expected for the second quarter of 2011."
Most read news
Topics
Organizations
Other news from the department research and development
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.